Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc.
Source: insidermonkey.com
Page 9 - Michael Yee News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Yee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Yee Today - Breaking & Trending Today
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2024.
Source: yahoo.com
Gilead posts quarterly loss on acquisition charge, revenue rises 5%
(Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, accord...
Source: yahoo.com
Biogen (BIIB) Q1 2024 Earnings Call Transcript
BIIB earnings call for the period ending March 31, 2024.
Source: fool.com